Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Recurrence 3Neoplasm Metastasis 3Melanoma 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Cutaneous Squamous Cell Carcinoma 2Carcinoma, Basal Cell 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Lymphoma 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Merkel Cell 1Breast Neoplasms 1Advanced Non-Small Cell Lung Carcinoma 1Adenocarcinoma 1

Interventions

cemiplimab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Non-Small Cell Lung Carcinoma × cemiplimab × Clear all
NCT03430063 2022-11-03

A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer

Regeneron Pharmaceuticals

Phase 2 Terminated
28 enrolled 16 charts
Thoracic

Advanced Non-Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡